Johnson & Johnson faces a big test in its talc defense, with a new trial in St. Louis consolidating claims of nearly two dozen plaintiffs. More: With its case count climbing, Johnson & Johnson faces major test in talc defense
read moreIt is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer. More: NICE rejects Janssen’s Zytiga for early, aggressive
read moreUS regulators have approved a combination of Eli Lilly’s Alimta and MSD’s Keytruda as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. More: US nod for Alimta/Keytruda lung cancer combo Source:
read moreRoche’s Hemlibra will get a speedy review in the US for adults and children with haemophilia A without factor VIII inhibitors. More: Priority review for Roche’s Hemlibra Source: News
read moreIn a world first, the UK government has announced a new project to develop a fully-automated drug discovery facility to accelerate the production of new medicines and “transform” the pharma industry. More: UK to develop world’s first ‘hands-free’ drug discovery
read morePublic Health England has reported a 20 percent increase in cases of syphilis in just one year, marking the highest number since 1949. More: UK sees 20 percent hike in cases of syphilis Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals